Cargando…

Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment

Detalles Bibliográficos
Autores principales:	Spranger, Stefani, Gajewski, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991072/ http://dx.doi.org/10.1186/2051-1426-1-S1-O8

Ejemplares similares

Agonist anti-4-1BB plus neutralizing anti-CTLA-4 or -PD-L1 synergize to promote tumor regression by rescuing dying dysfunctional CD8+ T cells within the tumor microenvironment
por: Horton, Brendan, et al.
Publicado: (2015)

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
por: Spranger, Stefani, et al.
Publicado: (2014)

Agonistic 4-1bb antibodies in combination with inhibitory antibodies against CTLA-4, PD-L1 or LAG-3 ACT on CD8+ T cells in the tumor microenvironment and synergize to promote regression of established tumors
por: Horton, Brendan, et al.
Publicado: (2014)

Melanoma-intrinsic β-catenin signaling prevents T cell infiltration and anti-tumor immunity
por: Spranger, Stefani, et al.
Publicado: (2014)

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer
por: Dhodapkar, Kavita, et al.
Publicado: (2014)

CTLA-4 checkpoint blockade in breast cancer, a case in point report
por: Dellepiane, Chiara, et al.
Publicado: (2015)

Characterization of oncogenic pathways linked with T cell exclusion in urothelial bladder cancer
por: Sweis, Randy F, et al.
Publicado: (2015)

The genetic landscape of the T cell non-inflamed tumor microenvironment in human solid tumors
por: Luke, Jason J, et al.
Publicado: (2015)

Adoptively transferred melanoma-reactive CTL primed in the presence of IL-21 and transferred with concurrent CTLA4 blockade results in enhanced CTL persistence and tumor regression
por: Yee, Cassian, et al.
Publicado: (2014)

IDO-induced immunosuppressive tryptophan catabolism following primary HIV infection
por: Jenabian, Mohammad-Ali, et al.
Publicado: (2014)

CTLA-4 based therapy (MDX-010)
por: Korman, A
Publicado: (2003)

Inducing a tolerogenic microenvironment within tissues
por: Cobbold, Stephen P
Publicado: (2011)

Direct activation of STING in the tumor microenvironment with synthetic cyclic dinucleotide derivatives leads to potent and systemic tumor-specific immunity
por: Corrales, Leticia, et al.
Publicado: (2014)

Chronic beta-adrenergic blockade prevents volume overload-induced re-localization and oxidation of soluble guanylyl cyclase
por: Liu, Yuchuan, et al.
Publicado: (2013)

S2. Therapeutic strategies based on overcoming immune resistance mechanisms within the melanoma tumour microenvironment
por: Gajewski, T
Publicado: (2014)

Cytomics of the tumour microenvironment: therapeutic targeting (keynote lecture)
por: Smith, Paul
Publicado: (2015)

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC
por: Della Corte, Carminia Maria, et al.
Publicado: (2022)

Immune surveillance is thwarted by tumor-cell intrinsic beta-catenin signaling
por: Spranger, Stefani, et al.
Publicado: (2015)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy
por: Chen, Jiang, et al.
Publicado: (2023)

Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models
por: Spahn, Jessica, et al.
Publicado: (2015)

Tissue resident memory T cells create genetically distinct immune microenvironments within melanoma metastasis
por: Dhodapkar, Kavita, et al.
Publicado: (2015)

Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity
por: Alvarez, Maite, et al.
Publicado: (2019)

Density of immunogenic antigens does not explain presence or absence of the T cell-inflamed tumor microenvironment in metastatic melanoma
por: Zha, Yuanyuan, et al.
Publicado: (2015)

The anti-tumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade
por: Dovedi, Simon, et al.
Publicado: (2014)

S43. Dendritic cell vaccination combined with CTLA4 blockade
por: Thielemans, K, et al.
Publicado: (2014)

CTLA-4 blockade: therapeutic potential in cancer treatments
por: Tarhini, Ahmad A, et al.
Publicado: (2010)

Combined radiotherapy and immunotherapy using CPG oligodeoxynucleotides and indolamine 2,3 dioxygenase (IDO) blockade
por: Monjazeb, Arta M, et al.
Publicado: (2013)

Sequential delivery of PD-1/PD-L1 blockade peptide and IDO inhibitor for immunosuppressive microenvironment remodeling via an MMP-2 responsive dual-targeting liposome
por: Hu, Chuan, et al.
Publicado: (2023)

CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade
por: Vackova, Julie, et al.
Publicado: (2021)

Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice
por: Affolter, Timothy, et al.
Publicado: (2019)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
por: Poon, Edmund, et al.
Publicado: (2017)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
por: Wu, Si-Pei, et al.
Publicado: (2015)

Using positive deviance (PD) to reduce antibiotic resistant organisms: the Canadian PD project
por: Reason, P, et al.
Publicado: (2011)

Stereotactic body radiation therapy and CTLA-4 blockade as a novel therapy for advanced melanoma
por: Twyman, Christina, et al.
Publicado: (2013)

Reversing gp100/IFA-induced impairment of anti-CTLA-4 checkpoint blockade therapy
por: Hailemichael, Yared, et al.
Publicado: (2014)

The effect of continuous interscalene nerve blockade on hospital length of stay following shoulder surgery
por: Udovicich, C, et al.
Publicado: (2012)

8. An autoinflammatory syndrome resembling Castleman’s disease with excellent response to IL-6 blockade
por: Chakravorty, Mithun, et al.
Publicado: (2019)

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
por: De Giglio, Andrea, et al.
Publicado: (2021)

P173 PK PD rationale and efficacy of isavuconazole treatment after failure of amphotericin B and posaconazole for COVID-19 associated cranial Mucormycosis
por: Soman, Rajeev, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tunp5ep31o9d5h73kbaqb96pti